Literature DB >> 21940419

Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.

Joseph N Jarvis1, Ann Percival, Sean Bauman, Joy Pelfrey, Graeme Meintjes, G Ntombomzi Williams, Nicky Longley, Thomas S Harrison, Thomas R Kozel.   

Abstract

BACKGROUND: Many deaths from cryptococcal meningitis (CM) may be preventable through early diagnosis and treatment. An inexpensive point-of-care (POC) assay for use with urine or a drop of blood would facilitate early diagnosis of cryptococcal infection in resource-limited settings. We compared cryptococcal antigen (CRAG) concentrations in plasma, serum, and urine from patients with CM, using an antigen-capture assay for glucuronoxylomannan (GXM) and a novel POC dipstick test.
METHODS: GXM concentrations were determined in paired serum, plasma, and urine from 62 patients with active or recent CM, using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). A dipstick lateral-flow assay developed using the same monoclonal antibodies for the sandwich ELISA was tested in parallel. Correlation coefficients were calculated using Spearman rank test.
RESULTS: All patients had detectable GXM in serum, plasma, and urine using the quantitative ELISA. Comparison of paired serum and plasma showed identical results. There were strong correlations between GXM levels in serum/urine (r(s) = 0.86; P < .001) and plasma/urine (r(s) = 0.85; P < .001). Levels of GXM were 22-fold lower in urine than in serum/plasma. The dipstick test was positive in serum, plasma, and urine in 61 of 62 patients. Dipstick titers correlated strongly with ELISA. Correlations between the methods were 0.93 (P < .001) for serum, 0.94 (P < .001) for plasma, and 0.94 (P < .001) for urine.
CONCLUSIONS: This novel dipstick test has the potential to markedly improve early diagnosis of CM in many settings, enabling testing of urine in patients presenting to health care facilities in which lumbar puncture, or even blood sampling, is not feasible.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940419      PMCID: PMC3193830          DOI: 10.1093/cid/cir613

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action.

Authors:  Joseph N Jarvis; Stephen D Lawn; Robin Wood; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2010-12-15       Impact factor: 9.079

2.  Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa?

Authors:  Joseph N Jarvis; Thomas S Harrison; Nelesh Govender; Stephen D Lawn; Nicky Longley; Tihana Bicanic; Gary Maartens; Francois Venter; Linda-Gail Bekker; Robin Wood; Graeme Meintjes
Journal:  S Afr Med J       Date:  2011-04

3.  Cryptococcal antigen detection from the urine of AIDS patients.

Authors:  K Chapin-Robertson; C Bechtel; S Waycott; C Kontnick; S C Edberg
Journal:  Diagn Microbiol Infect Dis       Date:  1993-10       Impact factor: 2.803

4.  Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme.

Authors:  Joseph N Jarvis; Graeme Meintjes; Robin Wood; Thomas S Harrison
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

5.  Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults.

Authors:  Neil French; Katherine Gray; Christine Watera; Jessica Nakiyingi; Eric Lugada; Michael Moore; David Lalloo; James A G Whitworth; Charles F Gilks
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

6.  Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.

Authors:  Ann Percival; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

7.  Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa.

Authors:  Joseph N Jarvis; Graeme Meintjes; Thomas S Harrison
Journal:  J Infect       Date:  2010-03-20       Impact factor: 6.072

8.  Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies.

Authors:  A Temstet; P Roux; J L Poirot; O Ronin; F Dromer
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

9.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Comparison of commercial kits for detection of cryptococcal antigen.

Authors:  D C Tanner; M P Weinstein; B Fedorciw; K L Joho; J J Thorpe; L Reller
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

View more
  117 in total

1.  Point-of-care urine antigen screening tests for tuberculosis and cryptococcosis: potential for mortality reduction in antiretroviral treatment programs in Africa.

Authors:  Stephen D Lawn; Robin Wood
Journal:  Clin Infect Dis       Date:  2011-12-21       Impact factor: 9.079

Review 2.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

3.  Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis.

Authors:  Richard Kwizera; Denis Omali; Kiiza Tadeo; John Kasibante; Morris K Rutakingirwa; Enock Kagimu; Kenneth Ssebambulidde; Darlisha A Williams; Joshua Rhein; David Boulware; David B Meya
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

4.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

Review 5.  Treatment principles for Candida and Cryptococcus.

Authors:  Laura C Whitney; Tihana Bicanic
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

6.  Cryptococcal Antigen Screening and Preemptive Treatment in a US Cohort of Patients With AIDS.

Authors:  Yukari C Manabe; Richard D Moore
Journal:  Clin Infect Dis       Date:  2015-07-13       Impact factor: 9.079

Review 7.  Reducing Uncertainty for Acute Febrile Illness in Resource-Limited Settings: The Current Diagnostic Landscape.

Authors:  Matthew L Robinson; Yukari C Manabe
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 8.  Point-of-Care Testing for Infectious Diseases: Past, Present, and Future.

Authors:  Thomas R Kozel; Amanda R Burnham-Marusich
Journal:  J Clin Microbiol       Date:  2017-05-24       Impact factor: 5.948

9.  Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Authors:  Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

10.  Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.

Authors:  Admasu Tenna Mamuye; Ethan Bornstein; Obsie Temesgen; Henry M Blumberg; Russell R Kempker
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.